Appili Therapeutics announces C$750,000 private placement

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) announced a non-brokered private placement offering up to 30 million units at C$0.025 per unit for gross proceeds of up to C$750,000.

Each unit consists of one Class A common share and one-half of one common share purchase warrant. The warrants will allow holders to purchase one common share at C$0.05 per share for 36 months from closing, subject to shareholder approval.

The Toronto Stock Exchange requires shareholder approval for the warrants before they become exercisable. Appili will seek this approval no later than its next annual general meeting. If shareholders do not approve the warrants, they will not be exercisable.

The Halifax-based biopharmaceutical company plans to use proceeds primarily for working capital and development of product candidates. The company focuses on drug development for infectious diseases and biodefense.

Certain finders will receive a cash fee equal to 8% of gross proceeds and broker warrants equal to 8% of units issued. The broker warrants will entitle holders to purchase common shares at no less than C$0.02834 per share for 24 months from closing, also subject to shareholder approval.

All securities issued will be subject to a statutory hold period of four months and one day from issuance. The private placement requires regulatory approvals, including TSX approval.

Appili anticipates closing the private placement in November 2025. The company is advancing anti-infectives including an FDA-approved metronidazole suspension, a tularemia vaccine candidate, and a topical antiparasitic treatment.

You May Also Be Interested In

• Amtech Systems closes $60 million public stock offering
• Mink Ventures raises $881,920 in first tranche of private placement
• OUTFRONT Media prices $500 million senior notes at 6% due 2034